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Medicalization of Mental Disorders: 1970 to the PresentOutline
1.  Introduction
2.  A Challenge to Organized Psychiatry--Psychiatry’s response 
3.  History of the Bio-Causation Movement
4.  Psychiatry Finds a Partner--Big Pharma
5.  The Impact of Direct-to-Consumer Advertising
6.  The Pharmaceutical Industry Extends its Reach
7.  Kids in the Crosshairs
8.  Medication Ads: The Serotonin-Depression “Connection”
9.  Medication Effectiveness
Outline, continued...
10.  The Congress and the FDA.  Will They Intervene?
11.  Pushback Begins
12.  Recommendations for Practioners:
• Know your history
• Recognize pharmaceutical industry tactics
• Have basic knowledge of psychotropic medications
• Avoid the vortex of medicalization
• Keep contact with the professional community (associations, etc.)
• Maintain a repertoire of brief, data-based treatments for a variety 
of client problems
• Be knowledgeable regarding research said to support bio-causation
The importance of this topic for practioners
• A 35-yr. escalation of emphasis on biological 
causation has rendered, for many, medications as 
the treatment of choice.
• Non-drug treatment may be cast aside, as a 
result.
A growing problem for therapists
• Psychiatric patients who also receive non-drug treatment:
• 1996-97 44.4%
• 2004-05 28.9%
Archives of General Psychiatry, 10-yr
survey of psychiatrists, August, 2008.
• When people believe their problems are biologically caused, 
they feel less responsibility…
• …and have less hope for improvement.
Phelan (2002)
Trends in Neuroscience
• Bio causation is related to prejudice, fear and desire for 
distance…
Haslam, Sayce, Davies (2006)
ACTA Psychiatrica Scandinavica

Difficult times for therapists, continued...
• Parents told to try behavioral interventions for their child (after 
which medication might be tried)… 95% did so.
• Parents given the drug prescription for their child, and also told 
to enroll the child in behavioral intervention programs…25% did 
so.
Pelham (2009)
A similar study...
Patients were given a prescription (anti-depressant) and told to 
follow up with non-drug therapy.
At three months later:
• Adults: Fewer than 25% had done so.
• Children: Fewer than 50% had done so.
Stettin, et. al, (2006)
Study of 80,000 adults (5,000 children) 2001 to 2003 by 
Managed care tracker Medco Health Solutions
And a related phenomenon…When medications become the treatment of choice
• Psychotropic medication errors result in 6,894 deaths 
per year in the U.S.
• Review of 31 pts’. Charts showed 2,194 medication 
errors (9 had been self-reported)…
• Over 400 million psychotropic prescriptions written in 
2004…
• Over half of psychotropic prescriptions are written by 
primary care physicians…
Grasso, et al, 
www.Medscape.com, 2007
And another...
• Looking at school shootings:
• Every school shooter was on psychotropic meds…
• Caveat: It is highly unlikely that medications  caused the 
shootings…
• However, a preference for medication may have precluded non-
drug intervention…
• …As families may have been convinced that other (non-drug) 
treatment was relatively less important.
A growing problem:
Increasing numbers of clients show up 
for therapy already convinced that 
their difficulties are cause by their 
biology:
• Their Genes
• A chemical imbalance
• exposure to a toxin
• etc.
Question:
Do you know someone who has 
taken prescription medication for 
depression?
Caution:
Some disorders are biologically determined, or 
partly biologically determined.
Autism
Tumor-related
Toxin-related
Endocrine & metabolic related
Genetic-related (Down’s syndrome, for example)
Others
Q: What is the empirical evidence that 
many instances of common disorders, 
such as:
• depression, 
• anxiety disorders,
• ADHD
• Schizophrenia
• Alcoholism
…are caused by genes, chemical imbalances 
or other bio phenomena? 
Consider one of these: Alcoholism
1954: The AMA declared it a “disease” 
Typical evidence cited: It runs in families; it 
ruins one’s health; it may cause death.
This was metaphor...
Alcoholism, continued...
Q:  But, isn’t there evidence of a genetic predisposition to 
alcoholism?
A: Yes.  But what behavior does such a predisposition cause?
Q:  ...and does such a predisposition rise to the level that we rightly 
term alcoholism a “disease”?
A:  It’s anybody’s guess.
MindFreedom sought answers:
July 28, 2003--MindFreedom wrote to three well 
established organizations that heavily promote 
the bio-causation model:
• American Psychiatric Association (APA)
• National Alliance for the Mentally Ill (NAMI)
• Office of the U.S. Surgeon General (OSG)
MindFreedom asked the three organizations several important questions:
Provide any scientifically valid evidence to show 
that:
• Schizophrenia
• depression
• other disorders, (aside from the obvious--
Down’s syndrome, autism, tumor-related, etc.)
…are biologically based.
MindFreedom also asked for any evidence for:
• Any physical diagnostic test that can reliably 
distinguish those so diagnosed, from “normals.”
• A chemically balanced “normal” personality, 
against which a neurochemical “imbalance” could 
be compared.
• How any psychotropic medication corrects a 
“chemical imbalance” or decreases likelihood of 
violence or suicide.
The American Psychiatric Association responded:
Two weeks later, August 12, 2003, a letter from 
James H. Scully, Jr., MD, Medical Director of APA 
wrote back:
“The answers to your questions are widely 
available in the scientific literature and have been 
for years…”
…and Dr. Scully advised MindFreedom to see these 
sources (next slide):
…see these sources:
• Introductory Textbook of Psychiatry, 3rd ed., (Andreason & 
Black, 2001)
• Textbook of Clinical Psychiatry (Hales & Yodofsky,  4th ed., 
2003)
• A recent report by the U.S. Surgeon General
• Any recent issue of the American Journal of Psychiatry
(Andreason, 2003) or the Archives of General Psychiatry
(Barchas, 2003).
MindFreedom checked those sources...
…and replied to Dr. Scully, and to the American 
Psychiatry Association, ten days later…
…The sources Dr. Scully had cited did not provide 
evidence in support of bio-causation of 
Depression, schizophrenia, etc.
Rather, (next slide)...
From Dr. Scully’s first suggested source...
Introductory Textbook of Psychiatry:
“Much of the current investigative research in psychiatry is 
directed toward the goal of identifying the 
pathophysiology and etiology of major mental illnesses, 
but this goal has been achieved for only a few disorders 
(Alzheimer’s disease, multi-infarct dementia, Huntington’s 
disease, and substance induced syndromes such as 
amphetamine-related psychosis or Wernicke-Korsakoff 
syndrome”) (p. 23).
From Dr. Scully’s next suggested source:
Textbook of Clinical Psychiatry
“Although reliable criteria have been constructed for many 
psychiatric disorders, validation of the diagnostic 
categories as specific entities has not been established” (p. 
43).
And from the next...
U.S. Surgeon General’s Report.
“The precise causes (etiology) of mental disorders are not 
known” (p. 49).
And from the journals that Dr. Scully had recommended...
MindFreedom wrote to Dr. Scully, asking that he 
refer to specific issues of the more than 200 
volumes of each journal...
Dr. Scully, Medical Dir. Of the American Psychiatric Association, replied, in writing, as follows:
• He provided no additional citations, references or 
empirical evidence in support of bio-causation.
• He provided an APA position statement that 
included the following precepts (next slide):
American Psychiatric Association’s position statement (continued)...
• …mental disorders are “neurobiological.”
• “…brain science has not advanced to the point where 
scientists or clinicians can point to readily discernible 
pathologic lesions of genetic abnormalities that in and 
of themselves serve as reliable or predictive biomarkers 
of a given mental disorder or mental disorders as a 
group…”
A conclusion
• The American Psychiatric Association 
urged a blind faith acceptance of the 
biological causation model of many 
common mental disorders.
Q: What has brought about this  
heightened acceptance of bio-
causation among both the 
public and professional 
cultures?
…and what does that mean for 
our non-drug treatment efforts?
One answer:The awesome power of direct-to-consumer advertising.Legalized in 1996

Another factor
Psychiatry’s answer to a crisis?
Embrace medicalization
…details to follow…
“Psychiatry’s Anxious Years”
NY Times (Nelson, 1982)
• 1970-1980—a drop in medical school grads 
choosing psychiatry---11% to 5%.
• Relatively low pay
• Family practice emphasis
• Psychoanalytic confusion
• Fringe Treatments & loss of esteem
• “Intruder” professions
Psychiatry’s response to this crisis?
Strategy conferences held.
Solution:
•Become more medical, and
•Attack the intruders
•The DSM-III (1980)
Organized psychiatry’s attacks on 
non-medical “intruders” quickly 
became vicious.
Some examples follow:
Hospital & Community Psychiatry (Bursten, 1981):
“Medicalization” of disorders is 
useful “to rally the troops…to 
thwart the attackers…Economics 
demands that we be medical…we 
use the term to rout the enemy 
within.”
Another example
• American Journal of Psychiatry (Havens, 1981)
“(Psychiatrists must) speak with a united 
voice…to buttress (our) position against the 
numerous other mental health 
professionals seeking patients and 
prestige.”
Another
• Paul Fink, President-elect of Am. Psychiatric Assn. 1988:
“(Non-psychiatrists) don’t have the training 
to make the initial evaluation and 
diagnosis…(and) are not trained to 
understand the nuances of the mind…”
And another
• Melvin Sabshin, Medical Director of the American 
Psychiatric Assn., testimony before the New York 
State Legislature, 1988:
“Do the grave and inevitable risks to the quality of 
patient and medical care in hospitals outweigh 
the dubious, purported benefits associated with 
hospital privileges for these non-physician 
practioners?”
Conclusion:
• Organized psychiatry’s 35-year emphasis upon 
biological causation has been motivated, in part, 
by non-science based factors including:
• Protection of its turf from “outsider” 
professionals
• Re-establishing its esteem
Big Pharma sees an opening
Pharmaceutical Company Financial Interests
Drug makers ask themselves, “How can we 
achieve symbiosis with organized psychiatry?”
Answer: Promote the biological causation 
model of disorders.
Big Pharma works its magic.Some examples follow.
The marketing of psychotropic medications:  Successful?
• 2001-2004:
• 49% increase in Rx of ADHD drugs in children 
under 5 years.
• 23% increase in overall usage of ADHD drugs.
Medco Health
Johnson, 2004
2001-2002
• Top ten revenue producing drugs included:
• Zyprexa
• Zoloft
• Paxil
• $7.5 billion in sales in the U.S.
Vaczek, 2003
2009
•Top ten revenue producing drugs included:
•Zyprexa
•Risperdal
•Effexor
$12.1 billion in sales in the U.S.
Health and Life (2010)
Adult use of ADHD drugs:
•100% increase – 2000 to 2004
Medco Health Solutions
AP, 9-16-2005
More children taking anti-psychotic drugs.
Children ages 2 to 5:
1999-2001 1 in 1,300  (appx.)
2007 1 in 630
5-yr-olds, only:
1999-2001 1 in 650
2007 1 in 329
Olfson (2010), Journal of the American Academy of Child & Adolescent Psychiatry.
1995-2000, the number of pharmaceutical industry 
jobs in:
…research & development fell by 2%,
…while jobs in marketing drugs rose by 59%
*Boston University Health Reform Project 
(Sagar & Socolar, 2001)
*Data obtained form the website of PhRMA
Direct-to-consumer advertising:  Its indirect effect on physicians’ prescribing practices.
Journal of the American Medical Association
(Kravitz, Epstein, Feldman, Franz, Azari, Wilkes, Hinton & Franks, 2005)
Subjects & Method:
152 family doctors were visited unannounced 298 times 
by actors posing as patients.  
The “patients” pretended to have symptoms of either 
major depressive disorder or adjustment disorder with 
depressed mood.
At some visits the “patients” said, “I saw an ad for Paxil on TV.  Doctor, do you think Paxil could help me?”
At other visits the “patients” said that they had seen an ad for “an 
anti-depressant” on TV, but didn’t specifically mention Paxil.
At still other visits the “patients” made no reference to 
medication.
Results
Rx of Paxil when the “patients” exhibited major depressive 
disorder*:
• Mention of “Paxil” 27.4% 
• Mention of “a drug” 2.0%
• No mention of drugs 4.2% 
*Similar percentages for adjustment disorder
Big Pharma’s impact on:
• American Psychiatric Association
•Congress 
•Several high profile psychiatrists
Pharma worked the American Psychiatric Association
• By 2006, the drug industry supplied 
about 30% of the financial support of 
the organization.
• Drug ads in psychiatry journals
• Exhibits at the annual conference
• Sponsorship of fellowships, conferences and industry 
symposia at the conference.
New York Times, July 12, 2008
Example: Pfizer*
2003 conference, San Francisco
*(Maker of Zoloft & Sinequan--antidepressants)
• Paid for 4 CE symposia, with 20 presenters.
• Each symposium included free dinner for attendees.
• Display booth, free copies of:
• The Memory Bible (Small, 2003)*
• The Quiet Room (Schiller & Bennett, 1996)*
*Books authors present to autograph their books.
American Psychiatric Association Clean-up Effort
March 2009--
• Announced it was ending free medical education seminars and 
meals sponsored at its conference by drug companies.
• (Earlier, drug makers had said they would stop giving out small 
gifts--pens, flash drives, etc.).
Mr. Pharma Goes to Washington
• 1998 to 2006:
• 1,400 bills
• $759 million spent on lobbying.
• More than 50 former House members working as 
lobbyists
• More than 12 former Senators also as lobbyists
• more than 800 other former federal officials 
working as lobbyists
Ismail 2006
PublicIntegrity.org
Big Pharma Pays Psychiatrists
• Dr. Charles B. Nemeroff, Emory University
• Dr. Frederick K. Goodwin, NPR
• Dr. Joseph Biederman, Harvard Medical 
School
• Dr. Alan Schatzberg, Stanford University
Dr. Charles B. NemeroffEmory University Medical SchoolFormer editor of Neuropsychopharmacology
• Principal investigator--$3.9 million 
grant from NIMH to study 
GlaxoSmithKline drugs.
• July 15, 2004, signed a letter to 
university officials stating he would 
earn less than $10,000 a year from GSK, 
to comply with federal rules.
…Dr. Nemeroff
•Same day, earned $3,000 for a GSK 
presentation in Jackson Hole 
Wyoming.
•Dr. Nemeroff’s  take from GSK that 
year?       $170,000.
…Dr. Nemeroff
• 2003--Failed to disclose financial ties to drug companies whose 
drugs he had favorably reviewed.  Blamed the journal.
• 2004--Emory Univ. conflict-of-interest committee revealed 
Nemeroff’s failures to disclose conflicts of interest in trials of 
drugs from Merck, Lilly, Johnson & Johnson.
…Dr. Nemeroff
• 2006--Failed to disclose financial ties to Cyberonics Co. 
controversial device he had reviewed favorably.  Blamed a 
clerical mix-up.  (Note: He edited that journal.) 
“…this paper was a paid piece of marketing,” 
Emory Associate Dean Claudia R. Adkinson
July 20, 2006. 
Dr. Frederick K. GoodwinFormer host, now-defunct NPR program, “The Infinite Mind”*
• Sept 20, 2005—On the air: “As we’ll be hearing today, modern 
treatments--mood stabilizers in particular--have been proven 
both safe and effective in bi-polar children…Left untreated, they 
could develop brain damage.”
*“The Infinite Mind” was heard in more than 300 markets.  It was 
canceled by NPR, following disclosures about Dr. Goodwin.
…Dr. Goodwin
• Same day--Was paid $2,500 by GSK for 
a promotional talk about its mood 
stabilizer, Lamictal, in Naples FL.
• That year--Was paid $329,000 by GSK.
…Dr. Goodwin’s reaction?
• “…it didn’t occur to me that my doing what 
every other expert in the field does might 
be considered a conflict of interest.”
and...
• “These companies compete with each 
other and cancel each other out” (because 
he consults for so many drug makers at 
once).
Dr. Frederick K. Goodwin
Dr. Joseph BiedermanHarvard Medical School
•Renowned child psychiatrist
•Proponent of anti-psychotic drugs 
for children
•Earned $1.6 million from drug 
makers, 2000-2007.
•Failed to report most of it to 
Harvard.
…Dr. Biedermanat the APA meeting, 2008
• From the Proceedings:
“In another industry-supported 
symposium, Joseph Biederman, MD, 
also laid out an enlightened view of the 
spectrum of bipolar disorder…”
• Report on proceedings at the meeting of the 
American Psychiatric Association, July, 2008.
Dr. Alan F. SchatzbergStanford University
• 2008--President-elect of American 
Psychiatric Association.
• Owned $4.8 million in stock in a drug 
development company.
Another conclusion:
• The pharmaceutical industry’s marketing 
efforts (to psychiatrists, Congress, 
consumers) have worked….
• Sales of medications, including 
psychotropic medications, have escalated 
at the same time.
Marriage
•Psychiatry •Pharmaceutial 
Industry
Cementing this marriage together is:
Biological causation theory
Reinforcers of this marriage:
Money and power
Big Pharma’s new target……children.
• U.S. Children diagnosed with bi-polar 
disorder:
1994………..20,000
2003………..800,000
Children’s use of anti-psychotic meds shows 
corresponding increase.
Olsen, et. al, Archives of Gen Psychiatry
2007
More Kids on Psychotropic Drugs
Of those, % on
One drug multiple drugs 
Netherlands 2.9% 8.5%
Germany 2.0% 5.9%
U.S. 6.7% 19.2%
Child & Adolescent Psychiatry and Mental Health,
October, 2008
U.K. anti-psychoticprescriptions for kids soar
• 1992…………….4 in 10,000 children
• 2005…………….7 in 10,000 children
The U.S.?  “We’re No 1”
• 1996……………23 in10,000 
• 2001……………45 in 10,000
Pediatrics, May, 2008
Florida Medicaid kids on anti-psychotic meds
• 2000 9,364 children
• 2006 18,137 children
Most common diagnosis for these children? 
ADHD, for which anti-psychotics are not 
approved.
Medicaid Review Panel finding, May 30, 2008
Advertizing and the “Serotonin-depression connection.”
First:The experts
“…the evidence (of a serotonin-depression connection) actually contradicts these claims.”Elliott Valenstein, 1998
“A serotonin deficiency for depression has not been found”
Joseph Glenmullen(2000)Harvard Medical School
“…I never saw any convincing evidence that any psychiatric disorder, including depression, results from deficiency of brain serotonin.”
David Burns, winner of the A. E. Bennett Award given by the Society for Biological Psychiatry for his research on serotonin metabolism.
“…no abnormality of serotonin in depression has ever been demonstrated.”
David Healy, former secretary of the British Association for Psychopharmacology, 2004.
“We have hunted for big simple neurochemical solutions for psychiatric disorders and have not found them.”
Kenneth Kendler, co-editor-in-chief ofPsychological Medicine, 2005.
“Advertisements that claim depression is 
caused by a chemical imbalance and 
that anti-depressants correct it, are 
false and should be banned.”
Jonathan Leo and Jeffrey Lacasse, 
Public Library of Science Medicine,  2007
“The chemical imbalance theory (of 
depression) is a ‘useful metaphor’ but 
shouldn’t be used when talking to patients.”
Wayne Goodman, Chair
Psychopharmacologic 
Advisory Committee
U.S. FDA
Does all of that matter?
Inquiring minds want to know.
Here are some examples of Big 
Pharma’s advertising.
“Celexa helps to restore the brain’s chemical imbalance.”
Forest Pharmaceuticals, 2005
“LEXAPRO appears to work by increasing the available supply of serotonin…In people with depression and anxiety, there is an imbalance of serotonin…”
Forest Pharmaceuticals, 2005
“When you’re clinically depressed…the level of serotonin …may drop…The medicine doctors now prescribe most is Prozac.”
Eli Lilly, 1998
“…depression may be related to an imbalance of natural chemicals…Zoloft works to correct this…”
Pfizer, 2004
“(Pristiq) is thought to work by changing the (brain’s) levels of norepinephrine and serotonin.” Wyeth Pharmaceuticles, April, 2010
Conclusion:
Pharmaceutical Industry 
advertising is not to be 
believed.
Anti-depressant and anti-psychotic medications—Are they effective, as advertized?
Studies are revealing.
Tofranil & Paxil: Common Antidepressants.
Sources: 6 studies; 718 patients took one of 
these meds for 6 to 11 weeks.
Findings: 
• Meds were no better than placebo, for mild to 
moderate depression (Hamilton Depression Scale 
scores below 23 (out of 50).
• Slightly better than placebo for severe depression.
Fournier, et. al (2010) 
JAMA
Another Review
Sources: 85 studies of 12 anti-depressants.
Findings:
• 37 of 38 that produced positive results 
were published
• 3 of 36 with negative results were 
published 
• 11 with negative or questionable results 
were written as if the drug had worked.
Turner, et al., NEJM, 2008
Another Review
Sources: 29 published and 11 unpublished randomized 
trials from five major databases on patients with acute 
moderate-to-severe major depression.
Findings: Paxil was better than placebo at improving 
symptoms but worse than placebo at causing dropout due 
to side effects.
Conclusion: “Paroxitine is not better than placebo in 
therapeutic effectiveness and acceptability in treating acute 
major depression.”
GeorgeD. Lundberg, Ed-in-Chief
The Medscape Journal of Medicine (2008)
Harvard School of Public Health
Another Review
• 38 Studies of anti-depressants (Zoloft, Paxil, Serzone, 
Celexa, Effexor, etc.), 1987 to 1999.
• Dependent measure: The 50-point Hamilton Depression 
Scale.
• Results:  
• Mean improvement, drug groups = 10 points
• Mean improvement, controls        =  8 points
Kirsch, et. al, (2002)
Prevention & Treatment
Yet another review:
Sources: 19 studies of top-selling 
anti-depressants.
Primary result: Placebo accounted 
for 75% of improvement.
Kirsch & Saperstein, 1998
Prevention & Treatment
Mood meds’ medical  methods
2-yr study of depression treatment (meds) by primary care 
physicians.
Results: 
• Over 40% did not follow long-term follow-up guidelines.
• Fewer than 40% met guidelines for patients who were non-
responsive to medication tx.
Hepner, et al,., Annals of Internal Medicine
Who knew?
Participants:  202 depressed adults:
Results: Group physical exercise just as helpful 
as medication.
Blumenthal, et al., Psychosomatic Medicine 
What about Anti-psychotic Medications?
A world-wide study showed 
anti-psychotic meds are used 
nearly as often as drugs that 
control cholesterol::
Maggon (2009)

Anti-psychotics are widely used...
...But there is a catch:
Discontinuation rate by 18 months 
(due to side effects):
64% to 82%,
(Depending on which anti-psychotic was 
taken.)
Leiberman, et. al, 2005
New England Journal of Med.
Alzheimers & antipsychotics
• Anti-psychotics given to 165 advanced Alzheimer’s patients 
provided no benefit for patients with mild behavioral problems, 
but were associated with marked deterioration in verbal skills.
• Up to 60% of Alzheimer’ s patients in nursing homes (in the UK) 
are given the drugs to control behavior such as aggression.
Report of the All-Party Parliamentary Group on 
Dementia Jeremy Wright, Chair, UK
Drug reps visit primary care doctors
• Primary care doctors have an average of 28
interactions weekly with drug company reps.
• If a drug rep got 1 min. with a doctor, the doctors 
prescription for that drug increased 16%.
• 3 min.—52%.
Basler, (2008). AARP Bulletin, 49,
20,24,26.
Anti-psychotic meds for the DD population?  A review of 8 studies
• “Antipsychotic drugs should no longer be regarded as an 
acceptable routine treatment for aggressive challenging behavior 
in people with intellectual disability.”
• Placebo showed greater change than anti-psychotics.
Tyrer, et al., Lancet (2008)
Will the Congress or the FDA intervene?
The Congress?  Who am I kidding?
• The pharmaceutical industry spent 
over $22 million lobbying congress in 
2007.
• As a result, efforts to limit drug 
industry advertising fell by the 
wayside.
The Congress, remember...
• More than 50 former members of the U.S. House 
of Representatives, and more than a dozen former 
U.S. Senators, now work as drug industry 
lobbyists.
• Over 800 former federal officials now are 
employed as drug industry lobbyists.
• There are far more drug industry lobbyists in 
Washington than members of Congress.
Will the FDA make significant changes?Not likely
• FDA: Science and Mission at Risk
• Inadequate staffing
• Poor retention
• Out-of-date technology
• General lack of resources
Report of the FDA’s Science Board, 2007
The FDA...
• …found “serious problems” at drug test sites 348 
times, 2000-2005. Only 26 investigators were 
disqualified from conducting further clinical 
studies.
Daniel Levinson
HHS Inspector General, 2007
FDA, cont’d...
• Bush administration removed FDA restrictions on 
off-label drug ads in medical journals.*
• Removed requirement that drug makers submit 
articles to FDA before sending them to doctors.
• *Off-label: Use of a drug for a non-FDA approved condition
Federal Prosecutors vs. FDA
• March 2009--Federal prosecutors said: 
(1)The antidepressants Lexapro & Celexa (both, 
Forest Pharmaceuticals) are no better than 
placebo for children, and...
(2) …the company swayed pediatricians with spa 
visits, fishing trips, tix to sports events & 
Broadway shows.
• Yet, April 2009--FDA approved Lexapro for 
adolescents.
Any Pushback?Anybody?
• Medical schools at: 
• Stanford
• Mount Siani
• Yale 
• U. Penn and others…
…Offer classes to teach medical students 
“how to effectively spar with the drug 
reps” by asking aggressive questions.
Dr. Ethan Halm, 
Mt. Siani School of Medicine, 
AP, November 2007
“Counter-detailers help doctors wade through drug company marketing.”Headline, Boston Globe, 2-26-07
The state of Pennsylvania hired 11 experts who made over 1,200 
visits to doctor’s offices to describe drugs’ actual benefits and side 
effects.
Drug industry trade group PhRMA said PA’s consultants are not held 
to same standards as drug company reps in their presentations.
AP, March 2008
JAMA2006
“Although physician groups, the manufacturers, 
and the federal government have instituted self-
regulation of marketing, research in the 
psychology and social science of gift giving 
indicates that current controls will not 
satisfactorily protect the interests of patients.”
Brennen, et.al, from paragraph 1, article titled  
“Health industry practices that create conflicts of 
interest.”
JAMACatherine De Angelis, MD, Editor -in-Chief
Impugning the Integrity of Medical Science: Adverse Effects of 
Industry Influence
“…profound influence from the pharmaceutical 
industry and medical device industries…because 
physicians have allowed it to happen.”
“…a glimpse of one company’s (Merck) apparent 
misrepresentation of research data and its 
manipulation of research studies…’
continued...
JAMAApril 16, 2008
• “Merck employees (were) working…to prepare manuscripts and 
subsequently recruiting external, academically affiliated 
investigators to be authors…”
• “Recruited authors were commonly the sole author on the 
manuscript and offered honoraria for their participation.”
Article on Rofecoxib litigation by J.S. Ross, et. al.
JAMA(Same article)
• Draft title (8 Merck scientists as authors)
Rofecoxib does not delay the onset of Alzheimer’s 
disease: Results from a randomized, double-blind, 
placebo-controlled study.
Published title, with added first, second & third authors from UCSD, 
NYU & Pivotal Research 
A randomized, double-blind, study of Rofecoxib in 
patients with mild cognitive impairment
JAMACatherine DeAngelis, M.D.Editor-in-Chief 
“The influence that the pharmaceutical companies, 
the for-profits, are having on every aspect of 
medicine…is so blatant now you’d have to be 
deaf, blind and dumb not to see it…We have just 
allowed them to take over, and it’s our fault, the 
whole medical community.”
Associated Press, Sept. 14, 2008
JAMAFebruary 10, 2009
Industry-sponsored Clinical Research: 
A Broken System
by
Marcia Angel, MD
“…sponsoring companies…often design the studies; 
perform the analyses; write the papers; and 
decide whether, when, and in what form to 
publish the results.”
Conclusions:
• Psychiatry has embraced non-science in order to 
protect its esteem and turf.
• Big Pharma has also thrown empiricism under the 
bus, regarding both biological causation and the 
effectiveness of psychotropic medications.
• Organized psychiatry and the pharmaceutical 
industry have become symbiotic: 
Bio-causation = drug treatment.
Recommendations for your practice.
Recommendation 1
Learn about the history of, and reinforcers 
for, adoption of the bio-causation model…
…Learn why, in our culture today, 
pills trump skills.
2
Understand the tactics of the pharmaceutical industry:
• Payoffs to physicians.
• Downplay of dangerous drug side-effects.
• Overstatement of drug effectiveness.
• Canceled studies where preliminary results were not 
positive.
• Ghostwritten studies.
• Etc.
3
Develop a working knowledge of 
psychotropic medications.
Common Anti-depressants*
• SSRIs: Paxil, Prozac, Zoloft, Desyrel, Pristiq, Celexa, 
Lexapro, Luvox.
• Side effects: OD may be fatal, nervousness, GI 
tract distress, headache, risk of suicide (esp. for 
children), sexual dysfunction, rash, agitation, 
weight gain, drowsiness, insomnia, restlessness, 
increased sweating. Takes 2-3 weeks to work.
*Note: The body of research indicates that placebo 
effects account for the majority of effectiveness of all anti-
depressants.
Anti-depressants, continued...
• Tri-cyclics: Elavil, Tofranil, Sinequan, Pamelor, Vivactil, 
Norpramin
• Side effects: OD may be fatal; colenergic antagonists (dry 
mouth, urine & feces retention), poor bp accomodation, 
decreased REM sleep.  Takes 2-3 weeks to work.
Anti-depressants, continued...
• MAOIs: Parnate, Nardil, Marplan.
• OD may be fatal, hypertension, stroke. Takes 2-3 weeks to work.
Anti-depressants, continued...
• *SNRIs: Effexor, Remeron, Ascendin.
• Side effects: OD can be fatal.
• Note: May work in about one week.
*Serotonin & Norepinephtine Reuptake 
Inhibitors
Anti-depressants, continued
• *NDRIs: Wellbutrin (Zyban)
*(Norephinephrine & Dopamine Reuptake 
Inhibitors.  AKA “Atypical antidepressants”)
• Side-effects: Generally the same as SSRI’s.  An exception is that 
NDRIs do not tend to cause sexual dysfunction.  Note: 
Wellbutrin is the only NDRI that is approved by the FDA.
Common  Anti-Anxiety meds
• Buspar, Klonopin, Librium, Serax, Valium, Vistaril, Zanaz, Ativan, 
Luvox, Prozac, Tranzene, Equanil, Halcyon, Versed.
• Side effects: Addiction, euphoria, difficult withdrawal, with 
overdose may appear dizzy or drunk.  (Note: Usually not life 
threatening)
Common Anti-Psychotic meds
• Haldol, Stelazine, Thorazine, Trilafon, Risperdal, Zyprexa, Clozaril, 
Geodon, Loxitane, Mellaril, Moban, Navane, Prolixin, Serontil.
• Side effects: Autonomic difficulties (cardio problems, etc.), EPS 
(tardive dyskinesia)*.
(Note: Usually not addictive, not life threatening if taken in OD)
*Note: Often other medications such as Artane and 
Cogentin are Rx’d simultaneously, to control the EPS.
Common drugs for mania
• Lithobid (lithium),  Depakote, Eskalith, Neurontin, Tegratol, 
Topamax.
• Side effects: Highly toxic, may cause tremors, cardio/renal 
difficulty.
Common drugs for ADHD
• Adderall, Ritalin, Concerta, Cylert, Dexadrine, Strattera, 
Metadate, Methylin
• Side effects: Especially in younger (age 6 and under) children, 
may cause irritability, crying spells, sleep disturbance.  Weight 
loss?  Addictive if used illegally.
Note: Typically not addictive if taken as Rx’d.  No need for 
step-down. 
4
Acknowledge that, at times, medications are 
effective.  Avoid a “drugs never helped 
anybody” approach.
5
Avoid sliding into the vortex of medicalization.  The 
world of psychiatric hospitals, psychiatry and the 
insurance industry can pull you in.
6
Stay in touch with the therapeutic community:
• Journals
• On-line discussions
• Associations
• Attend conferences
• Develop a support network.
7
For each client problem, have at the ready  a data-
based description that shows how a 
behavioral/non-medical method has worked with 
the same or a similar problem.
8
Have a working knowledge regarding the 
state of research that is usually cited as 
evidence of biological causation.
Some examples follow...
Jay Joseph and Johathan Leo De-construct Gottesman, 1991
Gottesman’s 1991 table is reproduced in many 
textbooks, but never had been critically analyzed 
until 2006:
Joseph, J. & Leo, J (2006). Genetic relatedness and the 
lifetime risk for being diagnosed with schizophrenia: 
Gottesman’s 1991 Figure 10 reconsidered. The Journal of 
Mind and Behavior, 27, 73-90.

From Gottesnam’s Table
• First-degree relatives’ concordance for schizophrenia:
• Children 13%
• Siblings 9%
• Sibs w/1 schizo parent 17%
• DZ twins 17%
• If one parent 6%
Weighted mean   = 11%-12%
(appx.)
(Note: population base rate =   1%)
From Gottesman’s table, cont’d
Concordance for:
MZ (identical) twins 48%
Offspring of dual matings 46%
A closer look at the Gottesman table
• Gottesman used only European studies, and mainly older studies 
(“…European populations between 1920 and 1987”)
• Done by investigators devoted to genetic theories who advocated 
sterilization of schizos.
• Done non-blind: They knew whether one sibling was schizophrenic, in 
determining concordance of the other.
• Vague, non-standardized diagnostic criteria.
More recent, U.S. studies
Author % of first-degree 
relatives concordant 
Tsuang, et. al. (1980) 4.3%
Pope, et. al. (1982) 0.0%
Abrams & Taylor (1983) 2.9%
Guze, et. al. (1983) 3.6%
Baron, et. al. (1985) 5.1%
Kendler, et. al. (1985) 3.6% 
Note: Studies included more than 2,000 bio relatives, 146 of whom had been 
diagnosed schizophrenic.
Deconstruction of Gottesman, cont’d
Gottsman used proband calculation method:
Proband method (What Gottesman used): 10 sib pairs, 3 of 
whom are concordant for 
schizophrenia.
3+3 6 = 46%  concordance 
10+3 13
Pairwise method (preferred).
3 = 30%  concordance
10
Gottsman deconstructed, cont’d
The same-sex vs. opposite-sex puzzle of DZ twins:
Same-sex DZ twins and opposite-sex DZ twins share the same 
amount of genetic material (50%).
Across 5 studies, 1934-1965, concordance rates:
Same sex DZ    =12.3% How do we explain this 
Opposite sex DZ=4.7% difference?
What to conclude from Gottesman’s review?
It provides little in the way of evidence to support genetic 
contributions to schizophrenia…
…and is contradicted by more recent studies that are better 
done and show a concordance rate of about 3.5% for 
schizophrenia among first degree relatives.
Shouldn’t we believe the studies of identical (MZ) twins who were reared apart?
They typically show concordance rates of 30%-50% for 
disorders such as schizophrenia.
Confounds include:
• Family adoption practices, often economics driven. 
• Equal levels of physical attractiveness
• Equal rates of reaching puberty
• Adoption agency practices
• Ages of adoption
Recommendation 8, cont’d...
What about: 
• Studies of brain imaging (fMRI; PET)?
• Studies done on autopsy?
Don’t  they show consistent differences between the brains of 
disordered patients and normals?
Yes, but they do not show the direction of causation. 
Another conclusion
The research commonly cited in support of biological causation 
of mental disorders comes from two areas:
1. Genetic family studies such as those described by 
Gottesman and…
2. Studies of brain imagery and chemistry.
The former are unconvincing, and the latter do not reveal the 
direction of causation.
Resources are available.
Here are some suggested sources:
Resources
Resources
Resources
Resources
Resources
Resources
Resources
Another resource
Primer on Psychotropic Medications
Matthew L. Israel
Available on the Judge Rotenberg Center website: www.jrc.org
Another resource
CriticalThinkRx.org
by
David Cohen
The End.
Thank you.
